BeyondSpring Phamaceuticals, Inc.
18Patents
18Active
18Granted
52Portfolio score
Filing activity: Jul 12, 2012 → Nov 19, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10238650B2 | Method of treating cancer associated with a RAS mutation | Human Necessities | 13 | Active |
| US10076518B2 | Method of treating a brain tumor | Human Necessities | 11 | Active |
| US10155748B2 | Plinabulin compositions | Chemistry; Metallurgy | 11 | Active |
| US10550104B2 | Plinabulin compositions | Chemistry; Metallurgy | 11 | Active |
| US10357491B2 | Method of treating a brain tumor | Human Necessities | 10 | Active |
| US8618292B2 | Analogs of dehydrophenylahistins and their therapeutic use | Chemistry; Metallurgy | 9 | Active |
| US10668063B2 | Method of treating cancer associated with a RAS mutation | Human Necessities | 9 | Active |
| US11045467B2 | Method of treating cancer associated with a RAS mutation | Human Necessities | 4 | Active |
| US10912748B2 | Compositions containing tucaresol or its analogs | Chemistry; Metallurgy | 4 | Active |
| US11254657B2 | Plinabulin compositions | Chemistry; Metallurgy | 2 | Active |
| US11229642B2 | Composition and method for reducing neutropenia | Human Necessities | 2 | Active |
| US11918574B2 | Method of treating cancer associated with a RAS mutation | Human Necessities | 1 | Active |
| US11786523B2 | Composition and method for reducing thrombocytopenia | Human Necessities | 1 | Active |
| US11400086B2 | Method of reducing chemotherapy-induced neutropenia | Human Necessities | 1 | Active |
| US11857522B2 | Compositions containing tucaresol or its analogs | Chemistry; Metallurgy | 1 | Active |
| US12024501B2 | Plinabulin compositions | Chemistry; Metallurgy | 1 | Active |
| US11633393B2 | Tubulin binding compounds and therapeutic use thereof | Human Necessities | 1 | Active |
| US12377094B2 | Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.